STOCK TITAN

T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences earnings
Rhea-AI Summary
T2 Biosystems, Inc. (NASDAQ:TTOO) will report financial results for Q4 and full year 2023 and business updates on February 15, 2024. A conference call will be held at 4:30 p.m. ET. Investors can access the live webcast at www.t2biosystems.com or dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 106354.
Positive
  • None.
Negative
  • None.

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2023 and business updates after market close on Thursday, February 15, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 106354, approximately ten to five minutes prior to the start time.

About T2 Biosystems:

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care through the rapid detection of bacterial and fungal pathogens which allow faster targeted antimicrobial treatment. T2 Biosystems’ products are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology and include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance® Panel, expanded T2Bacteria Panel to add Acinetobacter baumannii, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.

Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com 
415-937-5406


T2 Biosystems will report financial results for Q4 and full year 2023 on February 15, 2024.

Investors can access the live webcast at www.t2biosystems.com or dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 106354.

The conference call will begin at 4:30 p.m. Eastern Time.
T2 Biosystems Inc

NASDAQ:TTOO

TTOO Rankings

TTOO Latest News

TTOO Stock Data

Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Small Arms, Ordnance, and Ordnance Accessories Manufacturing
US
Lexington

About TTOO

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www